Recent clinical trial announcements have sparked excitement, and seem to be moving exponentially upwards!

However, enhancing the effectiveness of medications that target the adenosine route, overcoming obstacles related to resistance and immunosuppression, and boosting treatment for patients in need remain a huge challenge for the field.

This is why the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit is devoted to reuniting 80+ industry and academic thought leaders to analyze the most recent advances of the last year.

Across 3 days of jam-packed content, this meeting aims to improve understanding of adenosine signaling in the TME (tumor microenvironment), rationalize drug combinations to improve patient responses and explore tools that quantify adenosine to select the patient.

What's More? Check Out These Unmissable Highlights:

HW230208 2nd Adenosine-Pathway Targeted Cancer Immunotherapy logo ICON

Prepare for all outcomes of the pivotal phase 3 trial everyone is waiting for. Gain unique updates from leading pharma into how mAB candidates are advancing and what their plans are for future development with AstraZeneca

HW230208 2nd Adenosine-Pathway Targeted Cancer Immunotherapy logo ICON

Explore the core oncological concepts that underpin adenosine’s role in carcinogenesis. Learn how Adenosine induces hypoxia and angiogenesis mechanisms in cancer, and how targeting these improve patient outcomes with Harvard Medical School

HW230208 2nd Adenosine-Pathway Targeted Cancer Immunotherapy logo ICON

Use novel trial design concepts to gain an enhanced understanding of the interactions between Adenosine, PD/PDL-1 and other immunotherapies. Select the right combination partner or bispecific components with Phanes Therapeutics and Elpiscience

HW230208 2nd Adenosine-Pathway Targeted Cancer Immunotherapy logo ICON

Enhance your understanding of little-known components of the adenosine system. Gain a comprehensive understanding of the underpinning immunosuppressive mechanisms caused by adenosine signaling and enzymology with Rutgers University and the University of Turku

HW230208 2nd Adenosine-Pathway Targeted Cancer Immunotherapy logo ICON

Forecast the future of the adenosine field. Assess the potential outcomes of approval or major failure with ITeos Therapeutics and Trishula Therapeutics

Leave this definitive conference equipped with novel ideas, actionable lessons learned and new connections enabling you to progress your adenosine-pathway targeted cancer immunotherapies to the clinic.